Monoclonal antibody-based therapy has revolutionized MM therapy in the latest years increasing depth of response. This product review will focus on anti-CD38 monoclonal antibodies Daratumumab and Isatuximab efficacy, safety, pharmacokinetic …

In contrast, normal plasma cells and multiple myeloma (MM) cells have high levels of CD38 expression, which makes CD38 an interesting target for therapeutic antibodies targeting cell surface molecules in MM.

Nov 5, 2021 · By comparing CD38 positive and negative cells and using CD38 NADase inhibitor, we showed for the first time that CD38 on MM cells decrease intracellular NAD+, reduces intracellular glycolysis and as a result, has an influence on cell cycle.

Jan 4, 2018 · The relatively high expression of CD38 on MM cells, in combination with its role as receptor and ectoenzyme, suggested CD38 as a potential therapeutic antibody target for the treatment of MM.

Sep 20, 2018 · CD38-targeting antibodies have Fc-dependent immune effector mechanisms: complement-dependent cytoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cell-mediated cytotoxicity (ADCC).

Jan 4, 2018 · CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human).

Schematic representation of CD38 in promoting MM proliferation and preventing MM death. CD38 directs the cyclization of extracellular NAD + to intracellular cADPR (or ADPR) and triggers Ca 2+ release to cytoplasm in MM cells. Intracellular CD38 contributes to …

Nov 27, 2018 · Here, we summarized recent findings regarding CD38-targeted immunotherapy of MM in pre-clinical models and clinical trials, including (i) mAbs (daratumumab and isatuximab), (ii) radioimmunotherapy, and (iii) adoptive cell therapy, using chimeric antigen receptor (CAR)-transfected T cells specific for CD38.

CD38 is an effective target in some hematological malignancies such as multiple myeloma (MM). Daratumumab (Dara), a CD38-targeting antibody, can eliminate CD38 high immune suppressor cells and is regarded as a standard therapy for MM because of its outstanding clinical efficacy.

Apr 29, 2020 · We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies.